The market remained relatively static until 2021 when Novo Nordisks semaglutide (Ozempic for diabetes and Wegovy for obesity) was approved, showing nearly 10% weight loss over two years
The global G-protein coupled receptors market size is calculated at US$ 3.86 in 2024, grew to US$ 4.06 billion in 2025, and is projected to reach around US$ 6.37 billion by 2034
In Feb26, The US FDA accepted Roches Giredestrant NDA for ESR1-mutated, ER-positive advanced breast cancer Total Revenue: $60.4B Founded Year: 1886 Total Employees: 1,38,200 Headquarters: New Jersey, United States Market Cap: $581.22B Stock Exchange: NYSE JnJ is a diversified healthcare company with a strong pharmaceuticals segment (Innovative Medicine) alongside medical devices, focusing on oncology, immunology, neuroscience, and cardiovascular diseases
What to expect on a GLP-1 Your doctor may have warned you about the likelihood of nausea or other digestive side effects while taking a GLP-1 medication, but probably didnt go into detail about why these happen
ABSTRACT: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual glucose-dependent insulinotropic polypeptide/GLP-1 RAs are common therapies for managing diabetes and obesity, but gastrointestinal (GI) adverse effects (AEs) such as nausea, vomiting, diarrhea, and constipation frequently limit therapy
Biomedicines, 10 (2), 483
